ADMA
ADMA Biologics, Inc. · Healthcare
9.19
0.88%(+0.08)
Market Closed9.40
2.29%(+0.21)
After HoursLast Updated: — ET
52W L: $7.2152W H: $25.67
$9.25
CHG-6.39 (-40.86%)
H$16.40
L$7.23
VOL105M
ADMA (1h)
ADMA Biologics, Inc. · Healthcare
Cardiac Biotech Solutions (OTCMKTS:CBSC - Get Free Report) and ADMA Biologics (NASDAQ: ADMA - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Institutional and Insider Ownership 75.7% of ADMA
NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ:ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclosed Related Par.
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of ADMA Biologics, Inc. (NYSE: BCS) resulting from allegations that ADMA Biologics may have issued materially misleading business information to the investing public. So What: If you purchased ADMA Biologics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.
Kestenberg-Messina Kaitlin M.
officer: COO and SVP, Compliance
20,362 SH @ $9.11
2026-04-01
Guiheen Lawrence P.
director
30,000 SH @ $3.66
2026-03-13
Guiheen Lawrence P.
director
30,000 SH @ $0.00
2026-03-17
Guiheen Lawrence P.
director
30,000 SH @ $0.00
2026-03-17
Guiheen Lawrence P.
director
30,000 SH @ $3.66
2026-03-13
Grossman Adam S
director, officer: President and CEO
15,000 SH @ $5.40
2026-03-16
Grossman Adam S
director, officer: President and CEO
15,000 SH @ $15.16
2026-03-16
Grossman Adam S
director, officer: President and CEO
6,000 SH @ $15.16
2026-03-16